Review of clinical trials and benefit/risk ratio of meloxicam

Scandinavian Journal of Rheumatology, Supplement

Volumn 25, Issue 102, 1996, Pages 29-37

  Barner, A ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Clinical studies; Cyclooxygenase; GI safety; Meloxicam; NSAIDs

Indexed keywords

DICLOFENAC; MELOXICAM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PROSTAGLANDIN SYNTHASE; THIAZINE DERIVATIVE; THIAZOLE DERIVATIVE;

ABDOMINAL PAIN; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM PERFORATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DYSPEPSIA; ENZYME INHIBITION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; OSTEOARTHRITIS; PEPTIC ULCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; CHEMICALLY INDUCED DISORDER; FEMALE; GASTROINTESTINAL DISEASE; KIDNEY DISEASE; MALE; REVIEW; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; DOUBLE-BLIND METHOD; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; KIDNEY DISEASES; MALE; OSTEOARTHRITIS; RANDOMIZED CONTROLLED TRIALS; THIAZINES; THIAZOLES; TREATMENT OUTCOME;

EID: 0029867820     PISSN: 03013847     EISSN: None     Source Type: Journal    
DOI: 10.3109/03009749609097228     Document Type: Conference Paper

References (15)

1. Fries J. NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal. J Rheumatol 1991; 18(Suppl 28):6-10.
2. Giercksky KE, Huseby G, Rugstad HE. Epidemiology of NSAID-related gastrointestinal side effects. Scand J Gastroenterol 1989; 24(163):3-8.
3. Türck D, Busch U, Heinzel G, Narjes H. Clinical pharmacokinetics of meloxicam. Eur J Rheumatol Inflamm 1995; 15:23-30.
4. Verbeeck RK, Richardson CJ, Blocka KLN. Clinical pharmacokinetics of piroxicam. J Rheumatol 1986; 13:789-96.
5. Crevoisier Ch, Heizmann P, Forgo I, Durbach UC. Plasma tenoxicam concentrations after single and multiple oral doses. Eur J Drug Metab Pharmacokin 1989; 14:23-7.
6. Xie W, Robertson DL, Simmons DL. Mitogen-inducible prostaglandin G/H synthase: a new target for nonsteroidal antiinflammatory drugs. Drug Dev Res 1992; 25(4):249-65.
7. Vane J. Towards a better aspirin. Nature 1994; 367:215-6.
8. Engelhardt G. Meloxicam, a potent inhibitor of COX-2. Abstract presented at the 9th International Conference on Prostaglandins and Related Compounds. Florence, Italy, 6-10 June 1994.
9. Churchill L, Graham A, Farina P, Grob P. Inhibition of human cyclooxygenase-2 (COX-2) by meloxicam. Rheumatol Eur 1995; 24(Suppl 3):272.
10. Pairet M, Engelhardt G, Lidbury P, Vane JR. Differential inhibition of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) by meloxicam and its 4 isomer. Submitted for publication.
11. Mitchell JA, Akarasereenont P, Thiemerman Chr, Flower R, Vane JR. Selectivity of non-steroidal anti-inflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 1994; 90:11693-7.
12. Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1993; 268:6610-4.
13. CSM update. Non-steroidal anti-inflammatory drugs and serious gastrointestinal adverse reactions - 2. Br Med J 1986; 292:1190-1.
14. Langman MJ, Weil J, Wainwright P, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343:1075-8.
15. Garcia Rodriguez LA, Jick H. Risks of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343:769-72.